Edition:
United States

Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

32.21USD
21 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$32.21
Open
--
Day's High
--
Day's Low
--
Volume
5,935
Avg. Vol
188,260
52-wk High
$41.75
52-wk Low
$15.97

Chart for

About

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is... (more)

Overall

Beta: --
Market Cap(Mil.): $1,638.32
Shares Outstanding(Mil.): 50.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.22 16.52
EPS (TTM): -- -- --
ROI: -- 14.09 36.19
ROE: -- 15.56 17.38

BRIEF-Aimmune Therapeutics Announces Proposed Public Offering Of Common Stock

* AIMMUNE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 20 2018

Aimmune's peanut allergy drug meets main goal, shares surge

U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

Feb 20 2018

UPDATE 2-Aimmune's peanut allergy drug meets main goal, shares surge

Feb 20 U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study, sending its shares up 18 percent premarket.

Feb 20 2018

BRIEF-Aimmune Therapeutics' Phase 3 Palisade Trial Of Ar101 Meets Primary Endpoint In Patients With Peanut Allergy

* AIMMUNE THERAPEUTICS’ PIVOTAL PHASE 3 PALISADE TRIAL OF AR101 MEETS PRIMARY ENDPOINT IN PATIENTS WITH PEANUT ALLERGY

Feb 20 2018

Aimmune's peanut allergy drug meets main goal of key study

Feb 20 U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.

Feb 20 2018

BRIEF-Aimmune Extends Supply Agreement With Golden Peanut And Tree Nuts For Experimental Allergy Treatment

* AIMMUNE THERAPEUTICS BROADENS AND EXTENDS SUPPLY AGREEMENT WITH GOLDEN PEANUT AND TREE NUTS FOR AR101 FOR PEANUT ALLERGY

Jan 10 2018

BRIEF-Aimmune Therapeutics Inc Files For Potential Mixed Shelf

* AIMMUNE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF, SIZE NOT DISCLOSED - SEC FILING Source text (http://bit.ly/2ClRCUj) Further company coverage:

Dec 28 2017

BRIEF-Aimmune Therapeutics says ‍CEO Stephen Dilly plans to retire by end of 2018​

* Aimmune Therapeutics Inc announces third quarter 2017 financial results and planned retirement of CEO by the end of 2018

Nov 06 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Oct 16 2017

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Oct 16 2017

Competitors

  Price Chg
DBV Technologies SA (DBV.PA) €38.36 -2.06

Earnings vs. Estimates